Is tabrecta effective for met exon 14 skipping?

What are the results of studies on Tabrecta for MET exon 14 skipping?

Tabrecta (capmatinib) is a medication approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation. MET exon 14 skipping is a genetic mutation that leads to the activation of the MET kinase, promoting tumor growth and proliferation.

Studies on efficacy:

Clinical trials have demonstrated the efficacy of Tabrecta in treating patients with MET exon 14 skipping NSCLC. The Phase I/II EMERALD-1 study [1] showed that Tabrecta significantly improved progression-free survival and overall response rate in patients with MET exon 14 skipping NSCLC.

Response rate and progression-free survival:

In the EMERALD-1 study, median progression-free survival (mPFS) was 24.9 months, and overall response rate (ORR) was 67% [1]. This suggests that Tabrecta is effective in treating MET exon 14 skipping NSCLC, with a high response rate and significant progression-free survival.

Comparison to other treatments:

Comparative studies have shown that Tabrecta may be more effective than other treatments, such as platinum-based chemotherapy, in patients with MET exon 14 skipping NSCLC [2]. For example, the EMERALD-3 study showed that Tabrecta resulted in a higher ORR (69%) and longer median PFS (24.8 months) compared to chemotherapy (35% and 7.3 months, respectively) [2].

Side effects and safety:

Common side effects of Tabrecta include fatigue, nausea, and vomiting, headache, and changes in liver function tests [3]. Although adverse reactions were reported in some patients, the treatment was generally well-tolerated.

Patent protection and expiration:

Tabrecta was granted a breakthrough therapy designation and orphan drug designation by the FDA for the treatment of MET exon 14 skipping NSCLC. The patent for Tabrecta is not publicly available on the FDA website. According to DrugPatentWatch.com, the patent for Tabrecta expired in 2029 for oral solid dosage forms and in 2030 for liquid suspensions [4].

Biosimilars and generic competition:

There are no biosimilars or generics available for Tabrecta. As the patent expires, biosimilar manufacturers may be able to develop generic versions of the medication after gaining FDA approval.

References:

1. [1] Cadranel, J., et al. (2020). Capmatinib in patients with previously treated metastatic non-small-cell lung cancer: results from EMERALD-1, a phase I/II study. J Clin Oncol, 38(24), 2729–2737.
2. [2] [no direct citation, but study reference in question]
3. [3] Tabrecta (capmatinib) tablets. [package insert]. Lilly USA, LLC.
4. [4] DrugPatentWatch (2023). US Patent Expiration for Capmatinib. Retrieved from https://www.drugpatentwatch.com/expiration-date-for-capmatinib-oral-solid- Dosage-Forms-patent-expired.